Repurposing a Drug Targeting Inflammatory Bowel Disease for Lowering Hypertension
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background The gut and gut microbiota, which were previously neglected in blood pressure regulation, are becoming increasingly recognized as factors contributing to hypertension. Diseases affecting the gut such as inflammatory bowel disease (IBD) present
Xue Mei +7 more
doaj +1 more source
Cyanidin-3-glucoside suppresses cytokine-induced inflammatory response in human intestinal cells: comparison with 5-aminosalicylic acid. [PDF]
PLoS ONE, 2013 The potential use of polyphenols in the prevention and treatment of chronic inflammatory diseases has been extensively investigated although the mechanisms involved in cellular signaling need to be further elucidated.
Diana Serra +4 more
doaj +1 more source
5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis [PDF]
Intestinal Research, 2020 Background/Aims 5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between
Shinta Mizuno +14 more
doaj +1 more source
Resveratrol modulates cytokine-induced Jak/STAT activation more efficiently than 5-aminosalicylic acid: an in vitro approach. [PDF]
PLoS ONE, 2014 Many advances have been recently made focused on the valuable help of dietary polyphenols in chronic inflammatory diseases. On the other hand, current treatment options for intestinal bowel disease patients are unsatisfying and, for this reason, it is ...
Diana Serra +4 more
doaj +1 more source
Bulletin of the Chemical Society of Ethiopia, 2014 5-Aminosalicylic acid is an anti-inflammatory drug used in the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn’s disease.
K. Harveer, , S. Jasmeen
doaj +1 more source
Mesalazine induced focal segmental glomerulosclerosis in a patient with ulcerative colitis
Saudi Journal of Kidney Diseases and Transplantation, 2020 Focal segmental glomerulosclerosis (FSGS) and other glomerulonephritis due to the use of 5-aminosalicylic acid derivatives have been reported in the literature. A 38-year-old male who had been using mesalazine for four years because of ulcerative colitis
Fatih Yilmaz +3 more
doaj +1 more source
The culprit of mesalamine intolerance: case series and literature review
BMC Gastroenterology, 2019 Background Mesalamine is a first-line drug in the treatment of inflammatory bowel diseases, while its intolerance occasionally occurs in clinical practice.
Cheng Xie +5 more
doaj +1 more source
Canadian Journal of Gastroenterology, 1989 The knowledge that 5-aminosalicylic acid (5-ASA) is the active compound of sulphasalazine and that it acts topically has stimulated the use of 5-ASA containing enemas and ocher similar compounds such as olsalazine and 4-aminosalicylic acid (4-ASA). 5-ASA
M. Campieri +6 more
doaj +1 more source
Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan [PDF]
Intestinal Research, 2021 Background/Aims 5-Aminosalicylic acid (5-ASA) is a basic drug for inducing and maintaining remission for ulcerative colitis. One of its formulations has a coating with a pH-dependent degradation that ensures the release 5-ASA at the terminal ileum.
Yosuke Shimodaira +8 more
doaj +1 more source
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis [PDF]
Intestinal Research, 2018 Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been demonstrated, a few patients paradoxically develop a severe
Jun Miyoshi +12 more
doaj +1 more source